Cargando…

Clinical pharmacokinetics and dose recommendations for posaconazole gastroresistant tablets in children with cystic fibrosis

OBJECTIVES: To investigate the population pharmacokinetics of posaconazole gastroresistant tablets in children with cystic fibrosis (CF) and perform simulations to recommend optimal doses. PATIENTS AND METHODS: Children from a paediatric CF centre who had received posaconazole tablets and underwent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bentley, Siân, Davies, Jane C, Gastine, Silke, Donovan, Jackie, Standing, Joseph F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598294/ https://www.ncbi.nlm.nih.gov/pubmed/34458906 http://dx.doi.org/10.1093/jac/dkab312

Ejemplares similares

Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children
por: Boonsathorn, Sophida, et al.
Publicado: (2018)

Correction to: Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children
por: Boonsathorn, Sophida, et al.
Publicado: (2018)

Posaconazole‐induced hypertension in children with cystic fibrosis
por: Marpole, Rachael, et al.
Publicado: (2021)

Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections
por: Wiederhold, Nathan P
Publicado: (2015)

The Pharmacokinetic Profile of a New Gastroresistant Capsule Preparation of Eicosapentaenoic Acid as the Free Fatty Acid
por: Scaioli, Eleonora, et al.
Publicado: (2015)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetic/pharmacodynamic study of posaconazole delayed-release tablet in a patient with coexisting invasive aspergillosis and mucormycosis
por: Leelawattanachai, Pannee, et al.
Publicado: (2019)

Gelatin Films Modified with Acidic and Polyelectrolyte Polymers—Material Selection for Soft Gastroresistant Capsules
por: Maciejewski, Bartosz, et al.
Publicado: (2019)

Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease
por: Cornely, Oliver A., et al.
Publicado: (2016)

Posaconazole-Induced Hypertension Masquerading as Congenital Adrenal Hyperplasia in a Child with Cystic Fibrosis
por: Agarwal, Neha, et al.
Publicado: (2020)

Dosing Optimization of Posaconazole in Lung-Transplant Recipients Based on Population Pharmacokinetic Model
por: Dvořáčková, Eliška, et al.
Publicado: (2023)

Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation
por: Belling, Morgan, et al.
Publicado: (2017)

Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients
por: Sime, Fekade B., et al.
Publicado: (2018)

A Review of Population Pharmacokinetic Models of Posaconazole
por: Ding, Qin, et al.
Publicado: (2022)

A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers
por: Krishna, G., et al.
Publicado: (2012)

External evaluation of published population pharmacokinetic models of posaconazole
por: Huang, Shuqi, et al.
Publicado: (2022)

An automated approach to identify scientific publications reporting pharmacokinetic parameters
por: Gonzalez Hernandez, Ferran, et al.
Publicado: (2021)

1469 Posaconazole salvage treatment for invasive fungal infection : a single center experience with utilization of posaconazole oral suspension or delayed-released tablet
por: Kim, Jong Hun, et al.
Publicado: (2014)

Variation in Target Attainment of Beta‐Lactam Antibiotic Dosing Between International Pediatric Formularies
por: Gastine, Silke, et al.
Publicado: (2021)

Successful treatment of allergic bronchopulmonary aspergillosis with posaconazole in a child with cystic fibrosis: Case report and review of the literature
por: Yakut, Nurhayat, et al.
Publicado: (2020)

Posaconazole Pharmacokinetics in Healthy Cats after Oral and Intravenous Administration
por: Mawby, D.I., et al.
Publicado: (2016)

Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection
por: Allegra, Sarah, et al.
Publicado: (2017)

Comparison of Plasma Concentrations of Posaconazole with the Oral Suspension and Tablet in Korean Patients with Hematologic Malignancies
por: Suh, Hyeon Jeong, et al.
Publicado: (2017)

2546. Administration of Crushed Posaconazole Delayed Release Tablets Failed to Achieve Therapeutic Levels
por: Kane, Nicholas, et al.
Publicado: (2023)

Implications for IV posaconazole dosing in the era of obesity
por: Wasmann, Roeland E, et al.
Publicado: (2020)

Going the Extra Mile: Why Clinical Research in Cystic Fibrosis Must Include Children
por: Dobra, Rebecca, et al.
Publicado: (2022)

Nebuliser hygiene in cystic fibrosis: evidence-based recommendations
por: Bell, Jane, et al.
Publicado: (2020)

Hyperlipidemia Alters the Pharmacokinetics of Posaconazole and Vincristine Upon Co-Administration in Rats
por: Khalil, Hadeel A., et al.
Publicado: (2017)

Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia
por: De Gregori, Simona, et al.
Publicado: (2023)

Microflow Nanoprecipitation of Positively Charged Gastroresistant Polymer Nanoparticles of Eudragit(®) RS100: A Study of Fluid Dynamics and Chemical Parameters
por: Yus, Cristina, et al.
Publicado: (2020)

Posaconazole for lobomycosis
por: Pasqualotto, Alessandro C., et al.
Publicado: (2021)

Global antibiotic dosing strategies in hospitalised children: Characterising variation and implications for harmonisation of international guidelines
por: Clements, Michelle N., et al.
Publicado: (2021)

Effects of Posaconazole on Tacrolimus Population Pharmacokinetics and Initial Dose in Children With Crohn’s Disease Undergoing Hematopoietic Stem Cell Transplantation
por: Chen, Xiao, et al.
Publicado: (2022)

Oral Care Recommendation for Cystic Fibrosis Patients–Recommendation for Dentists
por: Pawlaczyk-Kamieńska, Tamara, et al.
Publicado: (2022)

The Effect of Posaconazole and Isavuconazole on the Pharmacokinetics of Erdafitinib in Beagle Dogs by UPLC-MS/MS
por: Ruan, Lan-hong, et al.
Publicado: (2021)

IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis
por: Kane, Zoe, et al.
Publicado: (2021)

Comment on: Population pharmacokinetics and dosing optimization of mezlocillin in neonates and young infants
por: Standing, Joseph F
Publicado: (2022)

Dose Optimisation of Posaconazole and Therapeutic Drug Monitoring in Pediatric Patients
por: Jia, Mengmeng, et al.
Publicado: (2022)

Pharmacokinetics of Micafungin in Critically Ill Patients
por: Gastine, Silke, et al.
Publicado: (2019)

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis
por: Floto, R Andres, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_54bg5fgdbc1ipsvgh8hf7gd6q9